# Eurofarma Laboratorios S.A. clinical trials: 64 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 64 trials with Eurofarma Laboratorios S.A. as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Eurofarma Laboratorios S.A.: 64 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/eurofarma-laboratorios-s-a

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 64
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 25 newest of 64, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 20, 2026 | NCT07714616 | Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose... | Eurofarma Laboratorios S.A. | Phase 3 | Not yet recruiting | Contraception | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714616) |
| April 14, 2026 | NCT07529977 | Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. | Eurofarma Laboratorios S.A. | Phase 3 | Not yet recruiting | Androgenetic Alopecia, Androgenetic Alopecia (AGA) | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529977) |
| January 6, 2026 | NCT07318350 | Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Moderate Asthma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318350) |
| December 24, 2025 | NCT07303322 | Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN) | Eurofarma Laboratorios S.A. | Phase 3 | Not yet recruiting | Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07303322) |
| July 9, 2025 | NCT07057479 | Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Type 2 Diabetes Mellitus (T2DM) | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07057479) |
| April 1, 2025 | NCT06905210 | Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris | Eurofarma Laboratorios S.A. | Phase 3 | Recruiting | Acne Vulgaris, Acne Vulgaris on the Face | 531 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06905210) |
| December 30, 2024 | NCT06752460 | Evaluation of the EF192B Protection Versus No Treatment | Eurofarma Laboratorios S.A. | Not applicable | Not yet recruiting | Skin Lesions, Skin Care | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752460) |
| December 12, 2024 | NCT06731062 | Assessment of EF192A Potential Sensitization and Accumulated and Primary Irritability in Controlled/Maximized Conditions | Eurofarma Laboratorios S.A. | Not applicable | Completed | Skin Lesion, Skin Lesions, Skin Care | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06731062) |
| December 4, 2024 | NCT06715462 | Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Painful Diabetic Peripheral Neuropathy (PDPN) | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06715462) |
| September 23, 2024 | NCT06608472 | Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Essential Arterial Hypertension | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06608472) |
| August 19, 2024 | NCT06560333 | iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Diabetes Mellitus, Type 2 | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06560333) |
| August 9, 2024 | NCT06546735 | Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.... | Eurofarma Laboratorios S.A. | Phase 3 | Not yet recruiting | Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | 816 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06546735) |
| January 31, 2024 | NCT06234345 | Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) | Eurofarma Laboratorios S.A. | Phase 3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 1,252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06234345) |
| June 5, 2023 | NCT05888311 | Evaluation of the Protection of a Liquid Bandage | Eurofarma Laboratorios S.A. | Not applicable | Completed | Skin Care | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05888311) |
| May 25, 2023 | NCT05876546 | Evaluation of Skin Irritancy and Sensitization of a Liquid Bandage | Eurofarma Laboratorios S.A. | Not applicable | Completed | Skin Care | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05876546) |
| February 21, 2023 | NCT05735431 | Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Moderate Asthma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05735431) |
| January 13, 2023 | NCT05683574 | Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Third Molar Extraction | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05683574) |
| December 5, 2022 | NCT05637710 | Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Allergic Rhinitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05637710) |
| January 31, 2022 | NCT05214911 | Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children | Eurofarma Laboratorios S.A. | Phase 3 | Completed | Allergic Rhinitis | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05214911) |
| January 27, 2022 | NCT05209997 | Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity | Eurofarma Laboratorios S.A. | Observational | Withdrawn | Overweight, Obesity | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05209997) |
| January 27, 2022 | NCT05209984 | A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight | Eurofarma Laboratorios S.A. | Phase 3 | Withdrawn | Overweight, Obesity | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05209984) |
| December 8, 2021 | NCT05148377 | UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit. | Eurofarma Laboratorios S.A. | Phase 3 | Completed | Hemodialysis Complication | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05148377) |
| November 12, 2021 | NCT05118672 | Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment | Eurofarma Laboratorios S.A. | Phase 3 | Completed | Cold, Flu Symptom | 567 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05118672) |
| October 18, 2021 | NCT05081102 | Fixed-dose Combination of Oxycodone \[OXIcodona\] + IbuproFEN in Pain Relief After Third Molar Extraction | Eurofarma Laboratorios S.A. | Phase 3 | Completed | Pain | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05081102) |
| July 22, 2021 | NCT04972292 | Fixed Dose Combination of COdeine + DIpyrone to Mitigate Moderate to Intense Pain Post-impacted Third Lower Molar Extraction | Eurofarma Laboratorios S.A. | Phase 3 | Completed | Pain | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04972292) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 2/3 | 1 |
| Phase 3 | 53 |
| Not applicable | 5 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 31 |
| Withdrawn | 22 |
| Not yet recruiting | 6 |
| Terminated | 4 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Asthma | 5 |
| Diabetes Mellitus, Type 2 | 4 |
| Rhinitis, Allergic | 3 |
| Alopecia | 3 |
| Pain | 3 |
| Osteoarthritis, Knee | 3 |
| Lactose Intolerance | 2 |
| Gastroesophageal Reflux | 2 |
| Breast Neoplasms | 2 |
| Hypertension | 2 |
| Overweight | 2 |
| Obesity | 2 |
| Rhinitis, Allergic, Perennial | 2 |
| Carcinoma | 2 |
| Adenocarcinoma | 2 |
| Insulin Resistance | 1 |
| Diabetes Complications | 1 |
| Metrorrhagia | 1 |
| Acne Vulgaris | 1 |
| Cystitis | 1 |
| Neutropenia | 1 |
| Angina, Unstable | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Osteoarthritis | 1 |
| Common Cold | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Community health centers in the United States](https://specstream.ai/data/businesses/community-health-centers/united-states)
- [Shoe factory manufacturers in the United States](https://specstream.ai/data/businesses/shoe-factory-manufacturers/united-states)
- [Gerontology practices in the United States](https://specstream.ai/data/businesses/gerontology-practices/united-states)
- [Alternative medicine clinics in the United States](https://specstream.ai/data/businesses/alternative-medicine-clinics/united-states)
- [Mobility equipment companies in the United States](https://specstream.ai/data/businesses/mobility-equipment-companies/united-states)
